F2RL2 (Coagulation Factor II Receptor Like 2)
Thrombin receptor PAR3; key mediator of protease-activated signaling in hemostasis and thrombosis
Gene Information Card
| Symbol | F2RL2 |
|---|---|
| Full Name | Coagulation Factor II Receptor Like 2 |
| Gene Type | protein-coding |
| Chromosomal Location | 5q13.3 |
| NCBI Gene ID | 2151 ncbi.nlm.nih.gov/gene/2151 |
| Ensembl ID | ENSG00000164220 |
| UniProt ID | O00254 |
| OMIM ID | 601919 |
| HGNC ID | 3539 |
| Aliases | PAR3, PAR-3, Thrombin receptor-like 2 |
Description
F2RL2 encodes protease-activated receptor 3 (PAR3), a G protein-coupled receptor activated by thrombin. PAR3 is expressed on platelets, endothelial cells, and various tissues, playing a critical role in thrombin signaling, platelet activation, and hemostasis. It forms heterodimers with PAR1 to mediate cellular responses to coagulation proteases.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Thrombosis | Gain-of-function variants enhance thrombin signaling leading to hypercoagulability | ClinVar, OMIM |
| Hemorrhagic disorders | Loss-of-function mutations impair platelet activation and clot formation | ClinVar, OMIM |
| Cancer metastasis | PAR3 overexpression promotes tumor cell invasion and metastasis via thrombin signaling | COSMIC, PubMed |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Blood (platelets) | 12.5 | Medium |
| Lung | 8.3 | Low |
| Kidney | 6.1 | Low |
| Brain | 4.7 | Low |
| Heart | 3.9 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK 293 | 15.2 | Moderate expression |
| A549 (lung cancer) | 9.8 | Detectable |
| MCF7 (breast cancer) | 7.4 | Low |
| HUVEC (endothelial) | 11.3 | Moderate |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.101C>T (p.Thr34Met) | Missense | <0.01% | Unknown functional effect; ClinVar |
| c.200G>A (p.Arg67His) | Missense | <0.01% | Likely benign; ClinVar |
| c.341A>G (p.Asn114Ser) | Missense | <0.01% | Uncertain significance; ClinVar |
Mutation functional classification
Loss of Function (LOF)
No confirmed loss-of-function variants reported in ClinVar or COSMIC for F2RL2.
Gain of Function (GOF)
No confirmed gain-of-function variants reported; however, overexpression in cancer may mimic gain-of-function.
Dominant Negative (DN)
No dominant-negative mutations described for F2RL2.
View complete mutation data：
Gene Ontology (GO)
| • G protein-coupled receptor activity | • thrombin-activated receptor activity |
| • signal transduction | • platelet activation |
| • cell surface receptor signaling pathway | • positive regulation of cytosolic calcium ion concentration |
Pathways
• Thrombin signaling and protease-activated receptors (PARs)
• Platelet activation
• signaling and aggregation
• GPCR downstream signaling
• Hemostasis
Protein Summary
PAR3 is a 374-amino acid transmembrane receptor with an extracellular N-terminal domain cleaved by thrombin, exposing a tethered ligand that activates the receptor. It couples to G proteins (Gq, Gi) to trigger calcium mobilization, MAPK signaling, and cytoskeletal rearrangements. PAR3 is essential for normal platelet function and vascular integrity.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| F2RL2 Knockout HEK293 Cell Line | EDJ-KQ4569 | Human | 2151 | Details Get a Quote |
| F2RL2 Knockout A-549 Cell Line | EDJ-KQ27224 | Human | 2151 | Details Get a Quote |
| F2RL2 Knockout HeLa Cell Line | EDJ-KQ53185 | Human | 2151 | Details Get a Quote |
| F2RL2 Knockout HCT 116 Cell Line | EDJ-KQ70148 | Human | 2151 | Details Get a Quote |
